{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 20 of 128', 'List of abbreviations', 'AE', 'adverse event', 'AS', 'area score', 'BSA', 'body surface area', 'CDISC', 'Clinical Data Interchange Standards Consortium', 'CI', 'confidence interval', 'CMO', 'contract manufacturing organisation', 'CRA', 'clinical research associate', 'CRO', 'contract research organisation', 'CTR', 'clinical trial report', 'DLQI', 'Dermatology Life Quality Index', 'ECG', 'electrocardiogram', 'eCRF', 'electronic case report form', 'eDiary', 'electronic diary', 'EMA', 'European Medicines Agency', 'ePRO', 'electronic patient-reported outcome', 'EQ-5D-5L', 'EuroQoL 5-Dimension Health Questionnaire 5-Level', 'GCP', 'Good Clinical Practice', 'HBcAb', 'hepatitis B core antibody', 'HBsAb', 'hepatitis B surface antibody', 'HBsAg', 'hepatitis B surface antigen', 'HDL', 'high density lipoprotein', 'HECSI', 'Hand Eczema Severity Index', 'HEIS', 'Chronic Hand Eczema Impact Scale', 'HESD', 'Chronic Hand Eczema Symptom Diary', 'HIV', 'human immunodeficiency virus', 'ICH', 'International Council for Harmonisation of Technical Requirements for', 'Pharmaceuticals for Human Use', 'IC50', 'half maximal inhibitory concentration', 'ID', 'identification number', 'IEC', 'independent ethics committee', 'IGA', \"Investigator's Global Assessment\", 'IGA TS', 'IGA treatment success, i.e. an IGA score of 0 (clear) or 1 (almost clear) with', 'at least a 2-step improvement', 'IgE', 'immunoglobulin E', 'IMP', 'investigational medicinal product']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 21 of 128', 'IND', 'investigational new drug', 'INN', 'international non-proprietary name', 'IRB', 'institutional review board', 'IRT', 'interactive response technology', 'JAK', 'janus kinase', 'LDL', 'low density lipoprotein', 'LEO', 'LEO Pharma A/S', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MMRM', 'mixed model for repeated measurement', 'NRS', 'numeric rating scale', 'PaGA', \"Patient's Global Assessment\", 'PaGATS', 'PaGA treatment success, i.e. a PaGA score of 0 (clear) when classified at', 'baseline as 1 (almost clear) or 2 (mild), or a PaGA score of 0 (clear) or 1', '(almost clear) when classified at baseline as 3 (moderate) or 4 (severe)', 'PDE-4', 'phosphodiesterase-4', 'PGI-C', 'Patient Global Impression of Change', 'PK', 'pharmacokinetics', 'PRO', 'patient-reported outcome', 'PT', 'preferred term', 'PUVA', 'psoralen and ultraviolet A', 'QOLHEQ', 'Quality of Life in Hand Eczema Questionnaire', 'SAE', 'serious adverse event', 'SD', 'standard deviation', 'SDTM', 'study data tabulation model', 'SOC', 'system organ class', 'SUSAR', 'serious and unexpected suspected adverse reaction', 'SS', 'severity score', 'STAT', 'signal transducer and activator', 'ULN', 'upper limit of normal range', 'UVB', 'ultraviolet B', 'WLQ', 'Work Limitation Questionnaire']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 22 of 128', '1 Protocol synopsis', 'Trial ID', 'LP0133-1273', 'EudraCT no.', '2018-000900-40', 'IND no.', 'CC', 'NCT no.', 'NCT03683719', 'Title of trial', 'A phase 2b, double-blind, randomised, 5-arm, vehicle-controlled, dose-ranging', 'trial to evaluate the efficacy and safety of twice daily topical application of', 'delgocitinib cream 1, 3, 8, and 20 mg/g for 16 weeks in adult subjects with mild', 'to severe chronic hand eczema', 'Short title of trial', 'Phase 2b dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg/g', 'compared to delgocitinib cream vehicle over a 16-week treatment period in', 'adult subjects with chronic hand eczema', 'Main objectives', 'Primary objective:', 'To establish the dose-response relationship of twice daily applications of', 'delgocitinib cream 1, 3, 8, and 20 mg/g and delgocitinib cream vehicle for', '16 weeks in the treatment of subjects with mild to severe chronic hand eczema.', 'Other objectives:', 'To compare the safety of twice daily applications of delgocitinib cream 1, 3, 8,', 'and 20 mg/g with delgocitinib cream vehicle for 16 weeks in the treatment of', 'subjects with mild to severe chronic hand eczema.', 'To evaluate the health-related quality of life and efficacy of twice daily', 'applications of delgocitinib cream 1, 3, 8, and 20 mg/g compared to', 'delgocitinib cream vehicle for 16 weeks in the treatment of subjects with mild', 'to severe chronic hand eczema.', 'To evaluate the effect of delgocitinib on Staphylococcus aureus colonisation of', 'the skin, skin microbiome, skin barrier function, and skin inflammation.', 'Primary endpoint', \"Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost\", 'clear) with at least a 2-step improvement (IGA treatment success [TS])', 'from baseline to Week 16.', 'Secondary', 'Change in Hand Eczema Severity Index (HECSI) from baseline to', 'endpoints', 'Week 16.', 'Time to IGA TS.', 'Final collection of', 'Week 16.', 'data for the', 'primary endpoint', 'Trial design', 'The trial is designed as a double-blind, multi-centre, randomised, 5-arm,', 'vehicle-controlled, parallel-group trial in which adult subjects with mild to', 'severe chronic hand eczema will be treated with delgocitinib cream 1, 3, 8, or', '20 mg/g or delgocitinib cream vehicle for 16 weeks.', 'The trial consists of a screening period, a treatment period, and a follow-up', 'period.']\n\n###\n\n", "completion": "END"}